Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Finished Goods (2021 - 2025)

Historic Finished Goods for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $14.5 million.

  • Rhythm Pharmaceuticals' Finished Goods rose 8097.08% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 8097.08%. This contributed to the annual value of $10.7 million for FY2024, which is 27012.09% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Finished Goods stood at $14.5 million for Q3 2025, which was up 8097.08% from $13.6 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Finished Goods ranged from a high of $14.5 million in Q3 2025 and a low of $111000.0 during Q4 2021
  • For the 5-year period, Rhythm Pharmaceuticals' Finished Goods averaged around $5.7 million, with its median value being $2.9 million (2023).
  • Its Finished Goods has fluctuated over the past 5 years, first surged by 7567.57% in 2022, then soared by 138461.54% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Finished Goods (Quarter) stood at $111000.0 in 2021, then skyrocketed by 75.68% to $195000.0 in 2022, then skyrocketed by 1384.62% to $2.9 million in 2023, then surged by 270.12% to $10.7 million in 2024, then skyrocketed by 35.71% to $14.5 million in 2025.
  • Its last three reported values are $14.5 million in Q3 2025, $13.6 million for Q2 2025, and $12.6 million during Q1 2025.